Treatment decision-making and treatment experiences in men with metastatic castration-resistant prostate cancer

The participants (median age: 77 years) generally reported high satisfaction with physician- and nurse communication and confidence/trust at baseline (>55% reported the highest satisfaction in all questions), but lower satisfaction with communication regarding how the treatments could affect them - up to 40% reported not having talked about that at all. Treatment experiences and physical- and emotional well-being remained stable over time. Associations were found between satisfaction with TDM at baseline and how they rated the treatment as a whole at six months, and well-being at six and 12 months. In mCRPC, men's TDM preferences need to be explored, and shared decision-making needs to be facilitated when considering treatment. Furthermore, clinicians need to discuss how the treatment might affect patients' everyday lives when discussing life-prolonging treatments with them.

Authors

Institutions

Publication Details

Journal
Acta Oncologica
Published
2025-03-24
DOI
https://doi.org/10.2340/1651-226x.2025.42748
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Treatment decision-making and treatment experiences in men with metastatic castration-resistant prostate cancer

Sandra Doveson, Agneta Wennman‐Larsen, Per Fransson, Lena Axelsson
Acta Oncologica
Prostate Cancer Treatment and Research
article

Treatment decision-making and treatment experiences in men with metastatic castration-resistant prostate cancer

Sandra Doveson, Agneta Wennman‐Larsen, Per Fransson, Lena Axelsson
article en

Abstract

The participants (median age: 77 years) generally reported high satisfaction with physician- and nurse communication and confidence/trust at baseline (>55% reported the highest satisfaction in all questions), but lower satisfaction with communication regarding how the treatments could affect them - up to 40% reported not having talked about that at all. Treatment experiences and physical- and emotional well-being remained stable over time. Associations were found between satisfaction with TDM at baseline and how they rated the treatment as a whole at six months, and well-being at six and 12 months. In mCRPC, men's TDM preferences need to be explored, and shared decision-making needs to be facilitated when considering treatment. Furthermore, clinicians need to discuss how the treatment might affect patients' everyday lives when discussing life-prolonging treatments with them.

Acta OncologicaVol. 64
Sophiahemmet University College (SE), Karolinska Institutet (SE), Marie Cederschiöld University (SE), Umeå University (SE)
Familjen Kamprads Stiftelse, Stiftelsen Silviahemmet
Peace, Justice and strong institutions
Openalex Percentile: Top 92%
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.